Project 1: Development of Skin Tissue Repair Materials through Omics-Based Discovery, Validation, and Application.Project 2: Discovery of Stem Cell-Derived Materials Using an Omics-Based Therapeutic Biomarker Screening Assay.Project 3: Development of Cas9 Ribonucleoprotein (RNP) Delivery Systems Targeting Specific Tissues/Tumors.Project 4: Mechanistic Study of Melanin Biosynthesis Inhibition in Skin.

- Supervised a team of 10 junior scientists, standardized protocols for RNA therapy platform development, and optimized workflows to enhance research productivity.- Demonstrated successful targeted payload delivery to tissues using immuno-fluorescence and qPCR.- Designed, developed, and validated a process to characterize the in vivo pharmacology (PK/PD, biodistribution), toxicity, viability, stability, safety, and efficacy of miRNA-loaded nanoparticles using molecular biology techniques including qPCR, ELISA, histology, WB and immunofluorescence.

As assistant research professor, my primary focus was on discovering novel physiological mechanisms of stem cell-derived EVs and their regulation of immune responses in models of immunodeficiency and age-related diseases. These studies were designed innovatively to produce high-yield EVs by stimulating the maturation of Multivesicular Bodies (MVB) using positively charged nanoparticles, which demonstrated physiological internalization pathways. All research was conducted based on preclinical studies and obtained Institutional Review Board (IRB) approval for the practical development of materials. This resulted in the submission of 6 patent applications, 7 publications as the first author, and the receipt of 3 grants from the Korean government.

Development of stem cell homing treatment technology based on Nanoparticles. - Defined immune signaling activation in hyperglycemic/aging patient samples. - Experience in nanoparticle characterization, size observation, morphology, and stability. - Drug Delivery: Proficient in designing and optimizing drug delivery systems for enhanced therapeutic outcomes.

Development of targeting gene delivery system platform by signal peptide sequence for melanoma. - Evaluated the anti-inflammatory/anti-cancer effect of microbiome-derived vacuoles. - Developed signal peptide sequence (PEP4/carboxypeptidase Y) mediated target gene delivery vectors. - Developed target gene delivery platform containing antioxidant/anti-inflammatory small molecules by formulation of lipid/metal conjugated nanoparticles (LNP/MNP).

As a senior research scientist in the respiratory virus laboratory, I led in designing research strategies to identify materials for the development of a vaccine platform against influenza and MERS viruses. In order to optimize the drug development process, our team collaborated with chemists and the animal department, transitioning to the pre-clinical stage by predicting the potential of materials through the development of methodologies and statistical analysis. The development of these models greatly contributes to optimizing the drug development process, facilitating informed decision-making and efficient allocation of resources.

- Demonstrated the mechanism of lysosomal storage disorders using knockdown models of lysosomal membrane proteins (LAMP1, LAMP2) and autophagy regulators (mTOR, TFEB).- Experience in developing animal models of lysosomal storage disorders for targeted therapy.